文献速递病毒性肝炎

恩替卡韦或富马酸替诺福韦二吡呋酯治疗慢性乙型肝炎期间功能性治愈的发生率及决定因素

Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B.
PubMed 文献 · J Infect Dis · 2021-01-01

这项国际多中心队列研究纳入4769例初治慢性乙型肝炎患者,随访中位5.16年,10年HBsAg清除累积发生率为2.11%,年发生率0.22%。基线低水平病毒血症、ALT>200 U/L、胆红素升高和脂肪肝与HBsAg清除独立相关。

要点

  • ETV或TDF治疗下HBsAg清除罕见,年发生率仅0.22%。
  • 基线HBV DNA<2000 IU/mL者HBsAg清除风险增加约3倍。
  • ALT>200 U/L、胆红素升高及脂肪肝亦与HBsAg清除相关。

核心结论

  • 慢性乙型肝炎患者接受ETV或TDF治疗期间HBsAg血清清除罕见发生。
  • HBsAg清除与基线低水平病毒血症、ALT flare、胆红素水平和脂肪肝相关。

研究设计与样本

  • 国际多中心队列研究,纳入4769例初治慢性乙型肝炎患者,基线无癌症,接受ETV或TDF治疗。

主要发现

  • 基线HBV DNA<2000 IU/mL的调整亚分布风险比为3.14(95%CI 1.80-5.49)。
  • 基线ALT>200 U/L的调整亚分布风险比为3.68(95%CI 2.07-6.53)。
  • 基线血清胆红素每升高1 mg/dL的调整亚分布风险比为1.11(95%CI 1.06-1.17 mg/dL)。
  • 基线脂肪肝的调整亚分布风险比为1.84(95%CI 1.03-3.29)。

临床怎么用

  • 对接受ETV或TDF治疗的慢性乙型肝炎患者,应告知HBsAg清除概率较低。
  • 基线低水平病毒血症、ALT flare、胆红素升高或脂肪肝的患者可能更易实现HBsAg清除,可加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term incidences and baseline determinants of functional cure (hepatitis B surface antigen [HBsAg] seroclearance) during entecavir (ETV) or tenofovir disoproxil fumarate (TDF) treatment are incompletely understood. METHODS: This is an international multicenter cohort study of treatment-naive patients with chronic hepatitis B who started ETV or TDF treatment without baseline cancer. Patients were observed for HBsAg seroclearance until death or loss to follow-up. We calculated the incidences and explored the baseline determinants of HBsAg seroclearance using competing risk regression. RESULTS: The analysis included 4769 patients (median age, 50 years; 69.05% male), with a median follow-up of 5.16 years (26 614.47 person-years). HBsAg clearance occurred in 58 patients, yielding a 10-year cumulative incidence of 2.11% (95% confidence interval, 1.54%-2.88%) and an annual rate of 0.22% (.17%-.28%). Baseline predictors included low-level viremia with hepatitis B virus DNA <2000 IU/mL (adjusted subdistribution hazard ratio, 3.14 [95% confidence interval, 1.80-5.49]), elevated serum alanine aminotransferase >200 U/L (3.68 [2.07-6.53]), serum bilirubin (1.11 per mg/dL; [1.06-1.17 mg/dL]), and fatty liver (1.84 [1.03-3.29]). CONCLUSION: HBsAg seroclearance rarely occurs in patients with chronic hepatitis B treated with ETV or TDF and is associated with low-level viremia, alanine aminotransferase flare, bilirubin level, and fatty liver.Functional cure of hepatitis B virus infection rarely occurred at an average annual rate of 0.22% during first-line oral antiviral treatment, with higher chances observed in patients with low-level viremia, high-level aminotransferase flare, elevation of serum bilirubin, and fatty liver.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hsu YC, Yeh ML, Wong GL, et al. Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. J Infect Dis. 2021. PMID: 33999179. doi:10.1093/infdis/jiab241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。